2026 Biomedical Pitch Competition
Day 2 Forum and Networking
70 seats available
Onsite Registration need to be done before 5/18
Theme: Bridging the Gap: From Lab to Market in a Global Ecosystem
Date: Sunday, May 24, 2026
Time: 9:00 AM – 12:30 PM (Half-Day Seminar)
Location:
Fish & Richardson P.C (Floor 17th) Conference Room
1 Marina Park Drive, Boston, MA 02210
Hosted by:
Boston Capital Investment Club (BCIC)
Hong Kong Science and Technology Parks Corporation (HKSP)
Event Overview
Following the 2026 Biomedical Pitch Competition, this seminar brings together international experts to bridge the ‘last mile’ of commercialization and facilitate strategic networking
Agenda
- 09:00 AM – 09:10 AM:Opening Remarks
- Jonathan Yi, President of BCIC
- 09:10 AM – 9:30 AM:Keynote I:
- Speaker: Weng-li Yoon, Associate Director from HKSTP
- Topic: Hong Kong as Asia’s Emerging Biotech Hub.
- 09:30 AM – 09:40 AM:Keynote II: Welcome from Venue Sponsor Fish & Richardson P.C.
- Speaker: Peng Lin, Partner of Fish & Richardson P.C.
- 09:40 AM – 11:00 PM:Panel Discussion: The Multi-Dimensional Launchpad
- A deep dive into VC, CRO, Regulatory, and Accelerator perspectives.
- Panelists:
- Weng-li Yoon, Associate Director from HKSTP
- Peng Lin, Partner of Fish & Richardson P.C
- Kate Zhang, Venture Partner of Venture Partner at Tailwinds (NLVC)
- Baolin (John) Wu, Executive Director of Technical Business Development
- Han Zhang, Managing Director of BCIC
- 11:00 PM – 12:30 PM: Hybrid Networking & Close
Registration Details
- In-Person: Limited seating (70).
- Fee: $20
https://bcic.ticketspice.com/2026-biomedical-pitch-competition-forum-and-networking-part
Keynote Speaker and Panelists Biographies
Wengli Yoon, Ph.D.
Associate Director (Therapeutics) of Hong Kong Science and Technology Parks Corporation (HKSP)
Weng Li is an R&D biotech leader with 20+ years of international experience in the startup and multinational corporation environment, based in the UK and Hong Kong.
In her current role at HKSTP, Weng Li and her team oversees the admission and support for all therapeutics companies in HKSTP with modalities such as small molecules, biologics, cell and gene therapy, Traditional Chinese medicine as well as nutrition. She also leads the Clinical Translational Catalyst which provides funding support for IND-enabling studies as well as clinical trials to HKSTP companies. In addition, she serves on the Joint Management Committee with Hong Kong University and the Chinese University of Hong Kong to establish the PIC/S GMP pilot manufacturing facilities for cell gene and therapy.
Peng Lin, Ph.D.
Principal of Fish & Richardson P.C.
Peng’s clients range from large publicly traded biopharmaceutical companies to emerging startup companies around the world. Peng has been involved at different growth stages of these companies, and he is dedicated to understanding his clients’ technology and developing the best intellectual property strategy to maximize the commercial value of his clients’ inventions.
Peng graduated cum laude from Harvard Law School. Prior to law school, Peng received his Ph.D. in human and statistical genetics from Washington University in St. Louis. Peng has extensive research experience and training in human genetics, molecular biology, biophysics, and bioinformatics. He advises his clients on patent matters relating to a broad range of technologies, including antibody therapeutics, transgenic animals, CAR-T immunotherapies, TCR-T immunotherapies, microarray technology, diagnostic methods, nanoparticle technology, vaccines, small molecules, medical devices, the application of artificial intelligence in the pharmaceutical industry, and related fields.
Peng is very actively involved in the Chinese entrepreneur community. He has been served as a volunteer of the Chinese Antibody Society since 2016 and is currently the president for the 2024-2026 term. The Chinese Antibody Society is a nonprofit organization dedicated to building a platform that facilitates the communication and collaboration of the global community in the discovery, development, manufacturing, and commercialization of antibody-based products.
Peng is a Kauffman Fellow for bio-entrepreneurship.
Kate Zhang, Ph.D.
Venture Partner of Venture Partner at Tailwinds (NLVC)
Dr. X. Kate Zhang, Ph.D., is a strategic scientific leader and executive with over 30
years of experience in the biopharmaceutical industry. Currently, she serves as a
Venture Partner at Tailwinds (NLVC), where she leverages her extensive background in
drug development to source investment opportunities and conduct deep scientific due
diligence on emerging biotech startups. Dr. Zhang previously served as the Chief
Scientific Officer and Interim CEO of Hopewell Therapeutics, where she spearheaded a
$25 million seed funding round and established a fully operational R&D infrastructure for
their tissue-targeting lipid nanoparticle (ttLNP) platform. Her career also includes
serving as VP of Biological Development at Editas Medicine, where she oversaw
landmark CRISPR-based IND submissions, and holding senior leadership roles at
Sanofi and Genzyme, contributing to the successful launch of ten biological drugs. An
accomplished researcher with over 45 peer-reviewed publications and multiple patents,
Dr. Zhang holds a Ph.D. from Queen’s University and completed post-doctoral training
at the National Institutes of Health (NIH).
Han Zhang (Moderator), Ph.D.,
Managing Director of Boston Capital Investment Club (BCIC)
Han Zhang (Moderator), PhD is the Managing Director of Boston Capital Investment Club (BCIC), where he supports connections among biotech founders, investors, and strategic partners across the life sciences ecosystem. He brings a cross-functional background spanning business development, competitive intelligence, biomedical informatics, and translational science. Earlier in his career, Han was part of the founding team at Annoroad Gene Technology and contributed to the company’s growth through its IPO journey. He has also held roles at Bristol Myers Squibb and SAS, building experience across biopharma, data science, and analytics. With training in biomedical informatics and a strong interest in commercialization strategy, Han focuses on bridging scientific innovation with market insight, partnering strategy, and investment dialogue.
Baolin (John) Wu, Ph.D.
Executive Director of Technical Business Development
Dr. Baolin (John) Wu is a seasoned leader in the pharmaceutical CRDMO industry, with
more than 12 years of experience spanning business development, account management,
process development and project leadership. He specializes in small-molecule
development and commercial manufacturing, supported by deep knowledge of ICH Q7-
compliant cGMP operations. Over the course of his career, Dr. Wu has worked closely
with global pharmaceutical and biotech partners on complex development and
manufacturing programs, and has managed strategic account portfolios exceeding US$30
million in annual revenue. Before taking on commercial leadership roles, Dr. Wu
contributed to more than 40 clinical and commercial manufacturing projects and over 50
development and commercialization programs across the United States and China. His
technical background includes process scale-up, technology transfer, continuous flow
chemistry, and enzymatic transformation. Dr. Wu received his PhD in Organic Chemistry
from Wayne State University and has coauthored 17 scientific publications in process
chemistry and related fields.
Co-organizers and Sponsors
| Name | Description |
| Boston Capital Investment Club (BCIC) | The Boston Capital Investment Club (BCIC) is a Massachusetts-registered non-profit organization serving nearly 10,000 professionals in finance, venture capital, and various technology industries. Beyond being a Boston-centered platform, the BCIC has grown to facilitate nationwide and international knowledge exchange across healthcare, finance, and related fields. Since 2022, the organization has hosted annual biomedical pitch competitions, empowering startups to secure over $300 million in collective funding.https://bcicglobal.org/ |
| Hong Kong Science and Technology Parks Corporation (HKSTP) | With a 20-year history of transforming lives through innovation, technology and entrepreneurship, Hong Kong Science and Technology Parks Corporation (HKSTP) has been propelling success for the most creative minds and innovators around the globe, accelerating ambitions and delivering positive impact from Hong Kong to the Greater Bay Area and the world. As an advocate for the innovative spirit, we strive to cultivate a diverse talent pool, connect research to innofacturing through “new industrialisation”, and create a well-established I&T ecosystem that bridges innovators with high-potential partners and investors for ideas to grow and thrive.https://www.hkstp.org/ |
| Fish & Richardson P.C. | As the leading IP law firm, we help innovators change the world through our unmatched litigation, prosecution, and post-grant experience across venues and prosecution needs. We touch more PTAB cases, IP appeals, and utility patents than anyone else, and no national firm handles more district court patent cases. Many of our 450+ attorneys and technology specialists are also scientists who are as comfortable in a lab or cleanroom as a courtroom or patent office. We’re ready to hit the ground running to support your innovations, while distilling our vast technical and legal knowledge to resonate with business leaders or juries. You can be confident in every Fish lawyer in your corner because we intentionally build talent from the ground up and share knowledge generously and eagerly across the firm, leading to faster, fuller insights for you. Visionaries across eras have trusted us to protect their IP — from Alexander Graham Bell to today’s largest phone makers — and we’re ready to help build your IP strategy today with tomorrow in mind. Let’s change the world together. |
| Shanghai InnoStar | Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar), was established in 2010. As a leading contract research organization, we adhere to the core values of “Science orientated, Quality first, Integrity & dedication, Win-win cooperation”, and strive for innovative and reputational services with high quality and excellence. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification GLPmonitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710). |
| Porton Pharma Solutions Ltd | Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages. |
| PanaCRO | PanaCRO is a full-service clinical CRO founded in 2004, helping global biotech and biopharma companies accelerate clinical development in China. With 500+ employees, coverage across 20+ provinces, collaboration with 800+ research sites, and experience supporting 200+ customers and 200+ clinical trials, PanaCRO provides end-to-end solutions from pre-IND/IND strategy and regulatory support to investigator-initiated trials (IITs), Phase I–III studies, NDA/BLA registration, and post-market real-world studies. With strong expertise in oncology, autoimmune diseases, infectious diseases, metabolic disorders, CNS, ophthalmology, and vaccines, PanaCRO combines deep local regulatory knowledge with international ICH-GCP standards to deliver efficient, high-quality clinical execution. As a trusted partner for innovative drug development, PanaCRO helps sponsors navigate China’s clinical and regulatory landscape with speed, quality, and confidence |
| Simcere Pharmaceutical Group | Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company with capabilities in R&D, production and professional marketing. It primarily focuses on the therapeutic areas of oncology, nervous system, autoimmune and antiinfection, with proactive forward-looking layout of disease areas that have significant clinical needs in the future, aiming to achieve the corporate mission of “providing today’s patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many MNC, innovative companies, research institutes and clinical centers. In addition, Simcere has established several R&D innovation centers around the world. One of the innovation centers is Boston Innovation Center, located in Cambridge. |
| Fenwick | Fenwick is a top law firm serving technology and life sciences clients. With 500+ attorneys, we are nationally recognized for strengths in complex transactions, IP protection, M&A, “bet‑the‑company” litigation, and domestic and international tax. Since the 1980s, we’ve advised on international outsourcing, IP enforcement, foreign investment, and cross‑border tax matters. Our lawyers combine deep technical knowledge with a commitment to efficient, high‑quality service in a collaborative environment. Fenwick’s landmark work includes incorporating Apple; pioneering the first shrink‑wrap license; negotiating an early software license with Bill Gates; taking Oracle, eBay, and 180+ others public; defending key biotech patents; and handling many of the industry’s largest and most significant mergers and acquisitions. |